昨日,乐普生物发布公告,公司截至2025年6月30日止六个月的未经审核综合管理账目及董事会现时所得数据的初步评估,预计公司将取得利润不少于人民币2400万元,上年同期则亏损约人民币1.97亿元。这是乐普生物首次实现盈利。乐普生物表示,报告期转亏为盈主要得益于收入的大幅成长,其中主要包括与ArriVent BioPharma,Inc.就MRG007开展的许可合作收入,以及普佑恒®(普特利单抗注射液)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.